About
Triglimisave 2mg is a triple-combination oral antidiabetic medication containing Glimepiride, Metformin, and Pioglitazone, designed for comprehensive glycemic control in adults with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates insulin release from pancreatic beta cells. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in peripheral tissues and the liver by activating PPARγ receptors. This synergistic combination addresses multiple facets of type 2 diabetes pathophysiology, including insulin deficiency, insulin resistance, and excessive hepatic glucose output. It is typically prescribed when dual therapy or monotherapy with these agents has not achieved adequate blood sugar control.
Uses
- Management of type 2 diabetes mellitus.
- Improvement of glycemic control in adults.
- Used when diet, exercise, and dual therapy are insufficient.
- Reduction of fasting and post-prandial glucose levels.
Directions For Use
Take this medication orally, usually once daily with a meal, as directed by your healthcare provider.
Benefits
- Comprehensive blood sugar control.
- Targets multiple diabetes mechanisms.
- Significantly lowers HbA1c.
- Improves insulin sensitivity.
- Reduces hepatic glucose production.
- Convenient fixed-dose combination.
Side Effects
- Hypoglycemia (due to Glimepiride)
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
- Weight gain
- Peripheral edema
- Lactic acidosis (rare, with Metformin)
- Bone fractures (with Pioglitazone)
- Heart failure (rare, with Pioglitazone)
- Upper respiratory tract infection
Safety Measures
- Alcohol - Avoid excessive alcohol consumption due to increased risk of hypoglycemia (with Glimepiride) and lactic acidosis (with Metformin).
- Pregnancy - Contraindicated during pregnancy. May cause fetal harm. Insulin is generally preferred for glycemic control in pregnant women.
- Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk.
- Liver - Contraindicated in active liver disease or severe hepatic impairment due to increased risk of lactic acidosis and liver toxicity.
- Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustment required for moderate impairment.
- Lung - Use with extreme caution in patients with a history of heart failure or pulmonary edema, as Pioglitazone can exacerbate fluid retention.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!